Co-Diagnostics, Inc. (CODX) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The company's financial performance showed a significant decline in revenue and an increase in net loss, which are negative indicators. The Co-Dx PCR testing platform, a key strategic initiative, is still pending regulatory approval, introducing uncertainty. The lack of discussion on shareholder returns and unclear management responses in the Q&A add to the negative sentiment. Given these factors, the overall outlook is negative, with potential for a -2% to -8% stock price movement.
Key Financial Performance
Revenue Co-Diagnostics reported revenue of $1.2 million for Q1 2026, a decrease of 40% year-over-year. The decline was attributed to reduced demand for COVID-19 testing products as the pandemic subsided.
Net Loss The company reported a net loss of $3.5 million for Q1 2026, compared to a net loss of $2.8 million in Q1 2025. The increase in net loss was due to higher operating expenses related to research and development for new diagnostic platforms.
Operating Expenses Operating expenses increased to $4.7 million in Q1 2026, up from $3.9 million in Q1 2025, representing a 20.5% increase. This was primarily driven by investments in R&D and personnel costs.
Gross Margin Gross margin for Q1 2026 was 50%, down from 60% in Q1 2025. The decline was due to lower revenue and a shift in product mix.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Co-Dx PCR testing platform: The platform requires regulatory approval and marketing authorization for diagnostic use and is not currently for sale.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Approval and Marketing Authorization: The company's Co-Dx PCR testing platform requires regulatory approval and marketing authorization for diagnostic use and is not currently for sale. This presents a risk as delays or failures in obtaining these approvals could impact the company's ability to commercialize the product.
Forward-Looking Statements: The company acknowledges that actual outcomes and results may differ materially from forward-looking statements, indicating potential risks in achieving projected goals or milestones.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Co-Dx PCR testing platform: Statements concerning the company's Co-Dx PCR testing platform, which requires regulatory approval and marketing authorization for diagnostic use and is not currently for sale.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Brian Brown
Brown CFO
CEO President
CFO Secretary
Chairman CEO
Diagnostics Inc
Diagnostics obligation
Division PM
Dwight Egan
EDT Co
Egan Chairman
Group LLC
Inc Webcast
Instructions conference
LLC Research
Maxim Group
Okunewitch Maxim
PM EDT
President Brian
Relations Dwight
Relations floor
Research Division
SEC Co
Secretary Okunewitch
Webcast Instructions
circumstance
conference Head
duty statement
event
floor factor
CODX Transcript
Co-Diagnostics, Inc. (CODX) Q1 2026 Earnings Call Transcript
Unknown5-14
The company's financial performance showed a significant decline in revenue and an increase in net loss, which are negative indicators. The Co-Dx PCR testing platform, a key strategic initiative, is still pending regulatory approval, introducing uncertainty. The lack of discussion on shareholder returns and unclear management responses in the Q&A add to the negative sentiment. Given these factors, the overall outlook is negative, with potential for a -2% to -8% stock price movement.
Co-Diagnostics, Inc. (CODX) Q4 2025 Earnings Call Transcript
Unknown4-1
The earnings call revealed significant challenges, including regulatory hurdles, decreased revenue, and increased expenses. The company's Co-Dx PCR platform, a key strategic initiative, faces regulatory and commercial adoption risks. Additionally, the financial performance showed declines in revenue, net income, and gross margin, with increased operating expenses. The lack of a shareholder return plan and unclear management responses further contribute to a negative outlook. Given these factors, the stock price is likely to experience a strong negative reaction.
Co-Diagnostics, Inc. (CODX) Q3 2025 Earnings Call Transcript
Unknown11-13
The earnings call reveals significant concerns: declining revenue, net losses, and financial dependency on external funding. Despite improved operational efficiency, the company faces multiple risks, including regulatory and international expansion hurdles. The Q&A section highlights management's lack of clarity on strategic initiatives, such as CoSara's spinout, further contributing to uncertainty. While there are promising developments, like the affordable PCR Pro and strategic partnerships, the overall sentiment is negative due to financial performance and unresolved risks.
Co-Diagnostics, Inc. (CODX) Q2 2025 Earnings Conference Call Transcript
Unknown8-14
The earnings report reveals significant revenue decline and ongoing net losses, with no immediate revenue boost expected from grants or partnerships. Despite reduced expenses, financial health remains weak. The Q&A section highlights uncertainties in clinical trials, regulatory approvals, and commercialization timelines, further dampening sentiment. Although operational efficiencies are noted, competitive pressures and economic uncertainties pose risks. Given these factors, a negative stock price reaction is anticipated over the next two weeks.
CODX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
